Return to search results.
Complete title: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma (The RELEVANCE Trial)
|Research Study Number||7636|
|Principal Investigator||Edward Libby|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Hematologic Malignancies; Lymphoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.